{"id":29344,"date":"2014-08-25T07:59:25","date_gmt":"2014-08-25T11:59:25","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=29344"},"modified":"2014-08-25T07:59:25","modified_gmt":"2014-08-25T11:59:25","slug":"biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344","title":{"rendered":"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment&#8217;s Phase 2A Study of CCH"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0According to reports, <strong>BioSpecifics Technologies Corp. (NASDAQ:BSTC)<\/strong> has announced statistically significant, positive double-blind, randomized phase 2A study of <a href=\"http:\/\/www.pharmabiz.com\/NewsDetails.aspx?aid=83722&amp;sid=2\">CCH<\/a>. One of the spokespersons of BSTC said that CCH was an ideal treatment of edematous fibro sclerotic panniculopathy or cellulite.<\/p>\n<p style=\"text-align: justify;\"><strong>Outcome of the study: <\/strong><\/p>\n<p style=\"text-align: justify;\">Results of this treatment showed that all the three doses i.e. high, medium and low dose improved the appearance of cellulite. The change in cellulite was measured by the patient-assessed improvements and the trial endpoints of physicians. The entire management of BioSpecifics Technologies Corp. (NASDAQ:BSTC)\u00a0including President Thomas L. Wegman looked so much encouraged and determined after the positive results. The results were equally encouraging for both patients and physicians because both of them saw a significant improvement in the cellulite appearance after CCH treatment.<\/p>\n<p style=\"text-align: justify;\">In the last few years, the market of cellulite treatment has grown a lot; therefore, these positive results have brought new possibilities and opportunities for CCH treatment. After the successful results, the management of the company is looking forward to taking the study on the next level.<\/p>\n<p style=\"text-align: justify;\">BioSpecifics Technologies Corp. (NASDAQ:BSTC)\u00a0executed The phase 2a study with the help of its strategic partner Auxilium Pharmaceuticals, Inc. Total 150 women between age group 18-45 were enrolled for this study. All of them received up to three treatment sessions of this drug randomly i.e. 5 high-dose 0.84mg (3 placebo : 5 low (0.06mg): 5 mid (0.48mg)). The average duration between all the treatments was 21 days that gave them enough time to measure the results of the previous studies. The doctors administered up to five injections during every session into cellulite dimples during the complete treatment session across the right posterior thigh or left\/right buttock. The researchers came to know that only dimples could be treated on day one, day twenty-two and day forty-three in case the\u00a0 dimple continued to be evident.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0According to reports, BioSpecifics Technologies Corp. (NASDAQ:BSTC) has announced statistically significant, positive double-blind, randomized phase 2A study of CCH. One of [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":29345,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[263],"tags":[8327,8328],"stock_ticker":[],"class_list":["post-29344","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology","tag-biospecifics-technologies-corp-nasdaqbstc","tag-nasdaqbstc","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment&#039;s Phase 2A Study of CCH - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment&#039;s Phase 2A Study of CCH - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0According to reports, BioSpecifics Technologies Corp. (NASDAQ:BSTC) has announced statistically significant, positive double-blind, randomized phase 2A study of CCH. One of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-25T11:59:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"265\" \/>\n\t<meta property=\"og:image:height\" content=\"85\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment&#8217;s Phase 2A Study of CCH\",\"datePublished\":\"2014-08-25T11:59:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg\",\"keywords\":[\"BioSpecifics Technologies Corp. (NASDAQ:BSTC)\",\"NASDAQ:BSTC\"],\"articleSection\":[\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344\",\"name\":\"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment's Phase 2A Study of CCH - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg\",\"datePublished\":\"2014-08-25T11:59:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg\",\"width\":265,\"height\":85},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment&#8217;s Phase 2A Study of CCH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment's Phase 2A Study of CCH - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344","og_locale":"en_US","og_type":"article","og_title":"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment's Phase 2A Study of CCH - Wall Street PR","og_description":"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0According to reports, BioSpecifics Technologies Corp. (NASDAQ:BSTC) has announced statistically significant, positive double-blind, randomized phase 2A study of CCH. One of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-25T11:59:25+00:00","og_image":[{"width":265,"height":85,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment&#8217;s Phase 2A Study of CCH","datePublished":"2014-08-25T11:59:25+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg","keywords":["BioSpecifics Technologies Corp. (NASDAQ:BSTC)","NASDAQ:BSTC"],"articleSection":["Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344","url":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344","name":"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment's Phase 2A Study of CCH - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg","datePublished":"2014-08-25T11:59:25+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/BioSpecifics-Technologies-Corp..jpg","width":265,"height":85},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biospecifics-technologies-corp-nasdaqbstc-announces-results-of-cellulite-treatments-phase-2a-study-of-cch-29344#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"BioSpecifics Technologies Corp. (NASDAQ:BSTC) Announces Results of Cellulite Treatment&#8217;s Phase 2A Study of CCH"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=29344"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29344\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/29345"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=29344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=29344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=29344"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=29344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}